Blakstad H, Brekke J, Rahman MA, Arnesen VS, Miletic H, Brandal P, Lie SA, Chekenya M, Goplen D(2023) Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions PLoS One, 18(2), e0281166 DOI 10.1371/journal.pone.0281166, PubMed 36730349
Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström Pet al.(2023) Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden BMJ Open, 13(3), e070071 DOI 10.1136/bmjopen-2022-070071, PubMed 36940951
Leske H, Blakstad H, Lund-Iversen M, Skovholt EK, Niehusmann P, Ramm-Pettersen JT, Skogen K, Kongelf G, Sprauten M, Magelssen H, Brandal P(2023) Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A Neuropathology, 43(5), 385-390 DOI 10.1111/neup.12895, PubMed 36754566
